)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SkyAI
SkyAI (SKYA) investor relations material
SkyAI Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Nov, 2026
Executive summary
Q3 net income was $84.9M, driven primarily by a $90.5M unrealized gain on SOL; 9M net loss was $24.6M, including $17.5M of realized digital-asset losses.
Strategy shifted from legacy medical-device operations and a SOL treasury toward development of an AI-enabled agentic finance platform, with Hong Kong established as the international operational headquarters.
Financial highlights
Q3 net income was $84.9M vs. a $105.3M loss YoY; 9M net loss was $24.6M vs. $99.8M YoY.
Q3 net revenue was $0 vs. $68,040 YoY; 9M revenue was $192,780 vs. $204,120, with a $294,026 gross loss after a $284,228 inventory reserve.
Q3 net staking revenue was $2.55M; 9M was $8.01M. 9M SG&A was $12.81M and R&D was $1.05M.
September 30 cash was $7.48M; total assets were $243.95M, including $231.43M of SOL at fair value, and stockholders’ equity was $241.16M.
Outlook and guidance
Following the October SOL sale, focus is on developing the agentic finance platform; management expects an additional ~$16M loss in Q4 from the sale.
Future AI development, commercialization and working capital are expected to be funded through equity and/or traditional financing until operations can fund requirements; no SOL repurchases are planned after the tender offer.
Results for the nine months are not necessarily indicative of FY 2026 results.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SkyAI
- Board rejects acquisition, backs Solana DAT strategy, and urges support for equity plan and nominees.SKYA
Proxy filing - Shareholders will vote on director elections, auditor ratification, and a new equity incentive plan.SKYAProxy filing
- $109.5M H1 net loss, Solana losses, rebrand, and new CFO amid AI finance platform pivot.SKYAQ2 2026
- Q1 2026 net loss was $86.2M, driven by large SOL losses and modest product and staking revenue.SKYAQ1 2026
- 2025 saw a $282.5M net loss amid a shift to a SOL treasury strategy and major capital raise.SKYAQ4 2025
- Hybrid medical device and SOL treasury strategy, with major warrant-driven capital raise.SKYARegistration Filing
- First revenues, $50M U.S. deal, and expansion into high-margin prefilled syringes drive growth.SKYALife Sciences Virtual Investor Forum
- $50M U.S. contract drives facility expansion and early revenue, with profitability targeted for 2025.SKYAAegis Capital Financial Conference
- Stockholders considered a reverse split, warrant issuance, and adjournment, with quorum met.SKYAStatus Update
Next SkyAI earnings date
Q4 202631 Mar, 2027
SkyAI
Next SkyAI earnings date
Q4 202631 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sharps Technology Inc. is a U.S.-based medical technology company specializing in the design and manufacturing of innovative safety syringes. The company focuses on developing solutions that enhance safety for healthcare professionals and patients by reducing the risks associated with needle stick injuries and improper disposal. The company is headquartered in Melville, New York, and its shares are listed on the Nasdaq Stock Market.